Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 4/20 | 0.84 |
| ▸ | PPARD | Q03181 | 4/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.30 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.30 |
| ▸ | CDK7 | P50613 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.30 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4881104 | 0.96 | VDR (0.77) | VDRPPARDPPARGPPARAFFAR1 | |
| SCHEMBL6564164 | 0.92 | VDR (0.77) | VDRPPARDFFAR1S1PR1MAOB | |
| SCHEMBL229168 | 0.91 | VDR (1.00) | VDRPPARDPPARGPPARAFFAR1 | |
| SCHEMBL6564192 | 0.91 | VDR (0.68) | VDRPPARDFFAR1S1PR1MAOB | |
| SCHEMBL2639763 | 0.89 | VDR (0.67) | VDRPPARDPPARGPPARAFFAR1 | |
| SCHEMBL2890000 | 0.89 | VDR (0.66) | VDRPPARDPPARGPPARAMAOB | |
| SCHEMBL4894574 | 0.89 | VDR (0.66) | VDRPPARDPPARGPPARAS1PR1 | |
| SCHEMBL4620770 | 0.88 | VDR (0.66) | VDR | |
| SCHEMBL4888601 | 0.87 | VDR (0.92) | VDRPPARDPPARGPPARAFFAR1 | |
| SCHEMBL2855063 | 0.87 | VDR (1.00) | VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4652687-B2 | — | — | 2011-03-16 | — | — | JP | claimed |
| US-20100286285-A1 | Pharmaceutical composition comprising oleaginous ointments and vitamin D or its derivatives in the solubilized state | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-11-11 | — | — | US | claimed |
| EP-1456160-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2010-01-20 | — | — | EP | claimed |
| EP-1893237-B1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ORGANOPOLYSILOXANE ELASTOMER AND A SOLUBILIZED ACTIVE PRINCIPLE | GALDERMA RES & DEV (FR) | 2009-09-16 | — | — | EP | claimed |
| US-20080194528-A1 | Pharmaceutical compositions comprising organopolysiloxane elastomers and solubilized bioactive compounds | GALDERMA RESEARCH AND DEVELOPMENT (FR) | 2008-08-14 | — | — | US | claimed |
| EP-1893237-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ORGANOPOLYSILOXANE ELASTOMER AND A SOLUBILIZED ACTIVE PRINCIPLE | Galderma Research & Development (FR) | 2008-03-05 | — | — | EP | claimed |
| WO-2006134272-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ORGANOPOLYSILOXANE ELASTOMER AND A SOLUBILIZED ACTIVE PRINCIPLE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-12-21 | — | — | WO | claimed |
| US-6924400-B2 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2005-08-02 | — | — | US | claimed |
| JP-2005511731-A | — | — | 2005-04-28 | — | — | JP | claimed |
| EP-1456160-A2 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2004-09-15 | — | — | EP | claimed |
| US-20030195259-A1 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-10-16 | — | — | US | claimed |
| WO-2003050067-A2 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2003-06-19 | — | — | WO | claimed |
| US-20100286285-A1 | Pharmaceutical composition comprising oleaginous ointments and vitamin D or its derivatives in the solubilized state | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-11-11 | — | — | US | disclosed |
| EP-1456160-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2010-01-20 | — | — | EP | disclosed |
| EP-1893237-B1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ORGANOPOLYSILOXANE ELASTOMER AND A SOLUBILIZED ACTIVE PRINCIPLE | GALDERMA RES & DEV (FR) | 2009-09-16 | — | — | EP | disclosed |
| US-20080194528-A1 | Pharmaceutical compositions comprising organopolysiloxane elastomers and solubilized bioactive compounds | GALDERMA RESEARCH AND DEVELOPMENT (FR) | 2008-08-14 | — | — | US | disclosed |
| US-6924400-B2 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2005-08-02 | — | — | US | disclosed |
| EP-1456160-A2 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2004-09-15 | — | — | EP | disclosed |
| US-20030195259-A1 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-10-16 | — | — | US | disclosed |
| WO-2003050067-A2 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286285-A1 | Pharmaceutical composition comprising oleaginous ointments and vitamin D or its derivatives in the solubilized state | CYP24A1, VDR, CYP2R1 | VDR 2/4885PPARD 10/4885PPARG 83/4885 |
| US-20030195259-A1 | Triaromatic vitamin D analogues | CYP24A1, CYP2R1, VDR | VDR 3/4885PPARD 61/4885PPARG 96/4885 |
| US-20080194528-A1 | Pharmaceutical compositions comprising organopolysiloxane elastomers and solubilized bioactive compounds | CYP24A1, VDR, SOST | VDR 2/4885PPARD 121/4885PPARG 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.